Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Whitney B Pope

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Scientific Reports|February 28, 2019
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistryArarat Chakhoyan, Jingwen Yao, Kevin Leu, et al.
Journal of Neuro-Oncology|September 2, 2022
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiationSatoka Shidoh, Ricky R Savjani, Nicholas S Cho, et al.
Journal of Neuro-Oncology|January 30, 2014
C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytomaNuraly K Avliyakulov, Kavitha S Rajavel, Khanh Minh T Le, et al.
Neuro-Oncology|May 9, 2019
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRIJingwen Yao, Ararat Chakhoyan, David A Nathanson, et al.
Iscience|August 30, 2020
Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet TherapyJantzen Sperry, Michael C Condro, Lea Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Neuro-Oncology|June 14, 2018
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placeboBenjamin M Ellingson, Lauren E Abrey, Josep Garcia, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy AssessmentXiao-Tang Kong, Nhung T Nguyen, Yoon J Choi, et al.
Neurosurgery|May 5, 2020
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor BurdenKunal S Patel, Richard G Everson, Jingwen Yao, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Scientific Reports|February 28, 2019
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistryArarat Chakhoyan, Jingwen Yao, Kevin Leu, et al.
Journal of Neuro-Oncology|September 2, 2022
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiationSatoka Shidoh, Ricky R Savjani, Nicholas S Cho, et al.
Journal of Neuro-Oncology|January 30, 2014
C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytomaNuraly K Avliyakulov, Kavitha S Rajavel, Khanh Minh T Le, et al.
Neuro-Oncology|May 9, 2019
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRIJingwen Yao, Ararat Chakhoyan, David A Nathanson, et al.
Iscience|August 30, 2020
Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet TherapyJantzen Sperry, Michael C Condro, Lea Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Neuro-Oncology|June 14, 2018
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placeboBenjamin M Ellingson, Lauren E Abrey, Josep Garcia, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy AssessmentXiao-Tang Kong, Nhung T Nguyen, Yoon J Choi, et al.
Neurosurgery|May 5, 2020
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor BurdenKunal S Patel, Richard G Everson, Jingwen Yao, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Pageof 13